Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study Neumora Therapeutics, Inc. has initiated a Phase 1 clinical study of NMRA-898, a M4 Positive Allosteric Modulator.
ASX Market Update The Australian stock market is experiencing a decline, led by significant losses in the healthcare and tech sectors, des…
Ericsson and Nokia Collaborate on 6G Video Research Nokia, Ericsson, and the Fraunhofer Heinrich Hertz Institute have presented a proof-of…
Bird Flu Strain H9N2: A Potential Threat to Humans A team of scientists has raised concerns about the H9N2 bird flu virus, which has adapt…
Isuzu FA Trophy Second Round Proper Draw Confirmed The draw for the Isuzu FA Trophy Second Round Proper has been confirmed, with 40 ties s…
Kymera Therapeutics Presents New Preclinical Data for KT-579 Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, announ…
Zenas BioPharma Announces Positive Results from Phase 2 MoonStone Trial Zenas BioPharma, a clinical-stage global biopharmaceutical company…
Waaree Secures 692MW Solar Module Deals Waaree Energies, an Indian solar manufacturer, has secured four solar module supply contracts tota…
Vesper Solar 600 MW Texas Project The Vesper Solar 600 MW Texas project demonstrates how an agrivoltaics mindset can unlock prime sites fo…
Can the Warriors Maximize Stephen Curry's Remaining Years? Stephen Curry remains an exceptional player, and his supporting cast has improv…
South Africa Approves Lenacapavir for HIV Prevention South Africa's Health Product Regulatory Authority (SAHPRA) has approved lenacapavir,…